Phosphodiesterase 4 inhibitors for psoriatic arthritis-Reference-Cited by-同舟云学术

Phosphodiesterase 4 inhibitors for psoriatic arthritis

Published:2016-10-15 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Zamora Natalia V¹,Valerio-Morales Ignacio-Alfredo²,Lopez-Olivo Maria Angeles¹,Pan Xin³,Suarez-Almazor Maria E¹

Affiliation:

1. The University of Texas, M.D. Anderson Cancer Center; Department of General Internal Medicine; 1515 Holcombe Blvd. Unit 1465 Houston Texas USA 77030

2. National Institute of Rehabilitation; Mexico City Mexico

3. Shanghai University of Traditional Chinese Medicine; Shanghai China

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012401/epdf/full

Reference62 articles.

1. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis;Aletaha;Clinical and Experimental Rheumatology,2005

2. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011;Armstrong;PloS One,2012

3. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs;Atteno;Clinical Rheumatology,2010

4. Cates C Visual Rx NNT Calculator 2008

5. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study;Clegg;Arthritis and Rheumatism,1996

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apremilast Microemulsion as Topical Therapy for Local Inflammation: Design, Characterization and Efficacy Evaluation;Pharmaceuticals;2020-12-21